Press Releases

Date Title and Summary View
March 24, 2016 Eleven Biotherapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Strategic Update View HTML
January 26, 2016 Albumedix and Eleven Biotherapeutics Announce Albumin Variant Technology Agreement
<i>Albumedix strengthens its leading position in albumin-based drug delivery through acquisition of Eleven's Supermin® albumin technology</i>
View HTML
January 15, 2016 Eleven Biotherapeutics Reports Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis View HTML
November 4, 2015 Eleven Biotherapeutics Reports Third Quarter 2015 Financial Results View HTML
October 27, 2015 Eleven Biotherapeutics to Report Third Quarter 2015 Financial Results on November 4, 2015 View HTML
October 15, 2015 Eleven Biotherapeutics Completes Enrollment in Pivotal Phase 3 Study of Isunakinra (EBI-005) in Patients with Allergic Conjunctivitis View HTML
September 1, 2015 Eleven Biotherapeutics Announces Promotions of Gary Sternberg, MD, MBA to Chief Business Officer and John McCabe, CPA to Senior Vice President, Finance View HTML
August 31, 2015 Eleven Biotherapeutics to Present at NewsMakers in the Biotech Industry Conference View HTML
August 13, 2015 Eleven Biotherapeutics Reports Second Quarter 2015 Financial Results View HTML
August 12, 2015 Eleven Biotherapeutics Announces First Patients Dosed with EBI-005 in Phase 3 Study in Patients with Moderate to Severe Allergic Conjunctivitis View HTML